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al., 2003). The structure of human PPCS determined atThe Final Player in the Coenzyme
2.3 A˚ resolution by Manoj et al. (2003) and presented inA Biosynthetic Pathway this issue of Structure now completes this pathway.
Investigation into the potential of these enzymes as
antibacterial targets is now an active area of research.
For example, Zhao et al. (2003) described recently po-
tent peptide inhibitors of E. coli PPAT, without activity
against porcine PPAT, discovered using an iterativeThe determination of the crystal structure of human
screening process based on knowledge obtained fromphosphopantothenoylcysteine synthetase completes
the crystal structure of E. coli PPAT cocrystallized withour knowledge of the enzyme structures involved in
an earlier lead inhibitor. The results of Gerdes et al. andall steps of coenzyme A biosynthesis. This structure
Zhao et al. indicate the value of structural informationprovides insight into the differences between bacterial
on the enzymes involved in CoA biosynthesis. Humanand mammalian forms of the enzyme and may guide
PPCS utilizes ATP and cysteine to convert phosphopan-the structure-based development of novel antibacte-
tothenate to phosphopantothenoylcysteine. Each mono-rial compounds.
mer in the homodimeric structure of human PPCS is a
 three-layer sandwich with a central eight-stranded
Coenzyme A (CoA) and its derivatives are essential co-
factors for4% of all cellular enzymes and participate in
numerous biochemical pathways in all living organisms.
CoA is synthesized from pantothenate (vitamin B5), cys-
teine, and ATP in five enzymatic steps, which were first
characterized by Abiko and coworkers in the 1960s (for
a summary see Abiko, 1975). These steps are (Figure
1): (1) pantothenate is phosphorylated to 4-pantothe-
nate by pantothenate kinase (PK), (2) addition of cysteine
by phosphopantothenoylcysteine synthetase (PPCS) to
yield (R)-4-phospho-N-pantothenoylcysteine, (3) de-
carboxylation to 4-phosphopantetheine by phospho-
pantothenoylcysteine decarboxylase (PPCDC), (4) transfer
of adenylyl group from ATP by phosphopantetheine ad-
enylyltransferase (PPAT) to form dephospho-CoA, and
(5) phosphorylation by dephosphocoenzyme A kinase
(DPCK) to obtain CoA. Despite the importance of this
pathway, only recently have the genes encoding all of
the CoA biosynthetic enzymes been identified and ex-
perimentally verified, both in humans (Daugherty et al.,
2002) and in bacteria (Kupke et al., 2000). A systematic
genetic footprinting study in E. coli by Gerdes et al.
(2002) confirmed the essentiality of the genes encoding
all five CoA biosynthetic enzymes. These studies identi-
fied significant dissimilarities between the bacterial and
eukaryotic enzymes within the CoA biosynthetic path-
way and highlighted the potential of the bacterial en-
zymes as targets for antibacterial drugs. For example,
the final two enzymes in the pathway, PPAT and DPCK,
are expressed separately in bacteria but form a bifunc-
tional enzyme complex in humans. Conversely, the sec-
ond and third enzymes in the pathway, PPCS and
PPCDC, form a bifunctional enzyme complex in most
bacteria but are expressed separately in humans. In
addition to the differences in oligomeric states, se-
quence similarity between the genes encoding ortholo-
gous enzymes is typically quite low, which is also true
for pantothenate kinase, which is expressed alone in all Figure 1. Coenzyme A Biosynthetic Pathway
organisms. To date, 3D structures have been determined
The important coenzyme A biosynthetic pathway has been charac-
for bacterial PK (Yun et al., 2000), plant PPCDC (Albert terized for some time—this figure is reproduced from the classic
et al., 2000), bacterial PPAT (Izard and Geerlof, 1999), textbook of Lehninger (1975), Biochemistry, Second Edition (New
York: World Publishers).and bacterial DPCK (Obmolova et al., 2001; O’Toole et
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in the N-terminal segment of the protein. The proteins 6100 Royalmount Avenue
Montre´al, Que´bec H4P 2R2classified within the SCOP database as having the ribo-
kinase-like fold include several kinases as well as pep- Canada
tide ligases from the Mur family. All of them utilize ATP
Selected Readingas a phosphate donor. PPCS on the other hand utilizes
ATP for an adenylation reaction. The structure of human
Abiko, Y. (1975). In Metabolic Pathways, D.M. Greenberg, ed. (New
PPCS demonstrates that the ribokinase-like fold accom- York: Academic Press), pp. 1–25.
modates a wider range of reactions and ATP binding Albert, A., Martinez-Ripoll, M., Espinosa-Ruiz, A., Yenush, L., Culia-
modes than previously thought. nez-Macia, F.A., and Serrano, R. (2000). Structure 8, 961–969.
Manoj et al. have also derived a model for the quater- Daugherty, M., Polanuyer, B., Farrell, M., Scholle, M., Lykidis, A.,
nary structure of the bifunctional bacterial PPCS/ Crecy-Lagard, V., and Osterman, A. (2002). J. Biol. Chem. 277,
21431–21439.PPCDC enzymes. The bifunctional enzyme from E. coli
was earlier demonstrated to be a dodecamer based on Gerdes, S.Y., Scholle, M.D., D’Souza, M., Bernal, A., Baev, M.V.,
Farrell, M., Kurnasov, O.V., Daugherty, M.D., Mseeh, F., Polanuyer,gel filtration measurements (Kupke et al., 2000). The
B.M., et al. (2002). J. Bacteriol. 184, 4555–4572.oligomeric states of the PPCS and PPCDC domains
Izard, T., and Geerlof, A. (1999). EMBO J. 18, 2021–2030.when expressed alone, in combination with the known
Kupke, T., Uebele, M., Schmid, D., Jung, G., Blaesse, M., andstructures of homologous proteins to these domains
Steinbacher, S. (2000). J. Biol. Chem. 275, 31838–31846.from humans (the present structure) and A. thaliana (Al-
Manoj, N., Strauss, E., Begley, T.P., and Ealick, S.E. (2003). Structurebert et al., 2000), suggest that the bifunctional enzyme
11, this issue, 927–936.consists of a PPCDC core surrounded by an outer layer
Obmolova, G., Teplyakov, A., Bonander, N., Eisenstein, E., Howard,of PPCS dimers. In the model presented, the two active
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the enzyme moves farther along the gene, phosphatesGetting a Grip
are increasingly found on S2 residues of the CTD repeats,on the CTD of Pol II and the S2-phosphorylated CTD is known to bind cleav-
age/polyadenylation factor subunits, such as Pcf11
(e.g., Licatalosi et al., 2002). However, because not much
is known about the structure of the CTD, whether free
The first structure of a pre-mRNA processing factor or factor bound, phosphorylated or unphosphorylated,
bound to heptad repeats from the C-terminal domain very little is known about the molecular details of CTD-
of RNA polymerase II is revealed in a crystal of capping protein interactions. A recent paper in Molecular Cell
guanylyltransferase complexed with a four-repeat provides a major boost to our knowledge in this area,
phosphopeptide. revealing how the phospho-CTD interacts with one of
its better-characterized binding partners, the guanylyl-
transferase component of pre-mRNA capping enzymeThe C-terminal repeat domain (CTD) of RNA polymerase
(Fabrega et al., 2003).II, composed of up to 52 repeats of the consensus hepta-
To date, only one structure showing a CTD repeat haspeptide Y1S2P3T4S5P6S7, contributes to the functional or-
been solved, that of mammalian Pin1 complexed withganization of the nucleus by mediating interactions be-
a canonical heptapeptide carrying Ser-PO4 at both posi-tween RNAP II and a lengthening list of nuclear factors.
tions 2 and 5 (Verdecia et al., 2000). The Pin1 structureActively transcribing RNAP II carries a highly phosphory-
provided a valuable first look at one CTD repeat boundlated CTD, which is known to recruit or tether certain
to a protein, but it also left many questions unanswered.RNA processing proteins to sites of transcription, posi-
In that structure, the single CTD repeat binds as antioning them to act on the nascent transcript (reviewed
extended coil, with 5 residues making contact with thein Bentley, 2002). As the polymerase begins to transcribe
protein (P3T4S5pP6S7). The phosphate on Ser5 makes sev-a gene, the CTD carries phosphates mostly on S5; this
eral contacts with the protein, which contribute signifi-form of the phospho-CTD efficiently binds 5 end cap-
cantly to the binding affinity. In contrast, the phosphateping components, such as capping guanylyltransfer-
ases (e.g., Komarnitsky et al., 2000; Pei et al., 2001). As on Ser2 points away from Pin1 into solution, not making
